Ameriprise
XENT

Ameriprise’s Intersect ENT, Inc XENT Stock Holding History

Ameriprise’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-157,397
Closed -$5.06M – 3814
2019
Q1 		$5.06M Buy
157,397
+4,512
+3% +$140K ﹤0.01% 2221
2018
Q4 		$4.31M Buy
152,885
+76,797
+101% +$2.25M ﹤0.01% 2220
2018
Q3 		$2.19M Buy
76,088
+29,915
+65% +$899K ﹤0.01% 2787
2018
Q2 		$1.73M Buy
46,173
+14,539
+46% +$571K ﹤0.01% 2791
2018
Q1 		$1.24M Buy
+31,634
New +$1.16M ﹤0.01% 2881
2017
Q4 		– Sell
-44,478
Closed -$1.39M – 3764
2017
Q3 		$1.39M Sell
44,478
-9,872
-18% -$292K ﹤0.01% 2808
2017
Q2 		$1.52M Buy
+54,350
New +$1.23M ﹤0.01% 2742
2016
Q2 		– Sell
-153,934
Closed -$2.92M – 3867
2016
Q1 		$2.92M Buy
153,934
+16,234
+12% +$294K ﹤0.01% 2301
2015
Q4 		$3.1M Sell
137,700
-215,766
-61% -$4.27M ﹤0.01% 2353
2015
Q3 		$8.27M Buy
353,466
+203,515
+136% +$5.62M 0.01% 1612
2015
Q2 		$4.29M Buy
149,951
+66,746
+80% +$1.75M ﹤0.01% 2247
2015
Q1 		$2.15M Buy
83,205
+23,669
+40% +$541K ﹤0.01% 2563
2014
Q4 		$1.1M Buy
59,536
+21,305
+56% +$383K ﹤0.01% 2838
2014
Q3 		$593K Buy
+38,231
New +$576K ﹤0.01% 2988

Other funds holding XENT

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ameriprise's XENT Position: Q2 2019 in Review

Ameriprise sold out of Intersect ENT, Inc (XENT) in Q2 2019, closing a stake of 157,397 shares — an estimated $5.06M sold.

Ameriprise first reported a position in XENT in Q3 2014 and held it in 14 quarters. The position peaked at $8.27M in Q3 2015. 112 funds tracked by Wall St. Rank hold XENT as of Q2 2019.

  • Ameriprise reported no remaining Intersect ENT, Inc position as of Q2 2019 after selling out during the quarter.
  • Ameriprise sold 157,397 Intersect ENT, Inc shares in Q2 2019, an estimated $5.06M.
  • Ameriprise first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 14 quarters.
  • Ameriprise's Intersect ENT, Inc position peaked at $8.27M in Q3 2015.
  • 112 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2019.

Based on Ameriprise's 13F filing for Q2 2019, filed 14 Aug 2019.